Skip to main content

Advertisement

Table 3 The rate of treatment-related adverse events of the study cohort

From: The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

Adverse event Frequency [cases (%)]
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
 Neutropenia 20 (30.8) 15 (23.1) 4 (6.2) 4 (6.2)
 Thrombocytopenia 9 (13.8) 2 (3.1) 0 0
 Anemia 24 (36.9) 3 (4.6) 0 1 (1.5)
Nonhematologic
 Loss of appetite 34 (52.3) 18 (27.7) 0 0
 Nausea 26 (40.0) 18 (27.7) 0 0
 Vomiting 14 (21.5) 19 (29.2) 1 (1.5) 0
 Mucosal inflammation 14 (21.5) 1 (1.5) 0 0
 Diarrhea 20 (30.8) 4 (6.2) 4 (6.2) 0
 Alopecia 52 (80.0) 13 (20.0)
 Fatigue 25 (38.5) 10 (15.4) 0 0
 Sensory neuropathy 18 (27.7) 3 (4.6) 0 0
 Weight loss 7 (10.8) 0 0 0
 Constipation 7 (10.8) 1 (1.5) 0 0
 Alanine aminotransferase elevation 22 (33.8) 7 (10.8) 1 (1.5) 0
 Aspartate aminotransferase elevation 12 (18.5) 4 (6.2) 0 0
 Bilirubin elevation 4 (6.2) 0 0 0
 Allergic reaction 1 (1.5) 0 0 0
 Rash 1 (1.5) 0 0 0
 Hand-foot syndrome 1 (1.5) 0 0 0
 Singultus 1 (1.5) 0 0 0